Can You Take Vitamin K2 If You Have High Blood Pressure?

Vitamin K2 is safe for most people with high blood pressure and does not raise blood pressure. A Cochrane systematic review of vitamin K supplementation for cardiovascular prevention found no effect of K2 on blood pressure or lipid levels, though it noted the evidence base was small.¹ In fact, there is a plausible biological reason K2 could help rather than harm your cardiovascular system if you have hypertension, though the clinical evidence for direct blood pressure reduction in humans remains thin and inconsistent.

Why K2 Gets Linked to Blood Pressure in the First Place

Vitamin K2 is not a blood pressure drug, and nobody prescribes it as one. The connection between K2 and blood pressure runs through a specific protein in your artery walls called matrix Gla protein, or MGP. MGP is one of the body’s main defenses against calcium building up in soft tissues where it does not belong, particularly inside arterial walls. But MGP needs vitamin K as a cofactor to become activated. Without enough vitamin K, MGP stays in its inactive form and cannot do its job.²³

When calcium accumulates in artery walls, the arteries stiffen. Stiff arteries lose their ability to expand and contract with each heartbeat, and that drives blood pressure up, particularly the systolic (top) number. This process is a well-documented contributor to isolated systolic hypertension, the most common form of high blood pressure in older adults.⁴ In healthy volunteers, the degree of aortic calcification was strongly correlated with aortic stiffness.⁵ So the theory goes: if K2 keeps MGP activated, and activated MGP keeps calcium out of artery walls, then arteries stay more flexible, and blood pressure stays lower. That chain of logic is solid on paper. The question is whether supplementing with K2 actually delivers measurable results.

What the Human Trials Actually Show

The most encouraging trial to date involved 244 healthy postmenopausal women who took 180 micrograms of MK-7 (the most commonly supplemented form of K2) daily for three years. By the end, the supplemented group showed meaningful improvements in arterial stiffness. Women who started with stiffer arteries benefited the most.⁶ A separate one-year trial in pre- and postmenopausal women found that MK-7 slowed the progression of vascular stiffness, and postmenopausal women who started with high baseline stiffness saw decreases in blood pressure at the brachial artery and carotid artery.⁷

That sounds promising, but other trials tell a different story. A randomized controlled trial in people with chronic kidney disease found no difference in arterial stiffness (measured by pulse wave velocity), blood pressure, or any cardiovascular marker after 12 months of vitamin K supplementation. The researchers also performed a meta-analysis of existing trials and concluded there was no overall effect on vascular stiffness or calcification.⁸ A multicenter trial of MK-7 in hemodialysis patients also found no significant improvement in arterial stiffness in the overall study population, though patients with diabetes in that trial did show a notable decrease in pulse wave velocity compared to controls.⁹

The pattern across trials is that K2 supplementation seems to help certain subgroups more than others, and those subgroups tend to be people who already have stiffer, more calcified arteries. The general population trials are either inconclusive or show null results. This is frustrating if you want a clear answer, but it is also where the science honestly stands.

The Vitamin D Connection

If you are taking vitamin D (or considering it) alongside K2, there is a piece of evidence worth knowing. A population study found that people with both low vitamin D and low vitamin K status had systolic blood pressure roughly 5 mmHg higher and diastolic blood pressure about 3 mmHg higher compared to people with adequate levels of both vitamins. The combination of low D and low K was also linked to a trend toward higher risk of developing hypertension.¹⁰ This was an observational study, so it cannot prove that supplementing with both vitamins would lower blood pressure. But it does suggest that the two vitamins may work together in ways that matter for vascular health. Vitamins D and K share overlapping roles in how the body handles calcium, and their partnership in keeping calcium in bones and out of arteries is sometimes called the “calcium paradox.”¹¹

Biomarkers Suggest K2 Status Matters Even When Trials Are Mixed

One reason researchers remain interested despite the mixed trial results is what biomarker studies show. When the body does not have enough vitamin K to activate MGP, a specific inactive form of that protein (called dp-ucMGP) accumulates in the bloodstream. Higher levels of this inactive form have consistently been associated with higher blood pressure, stiffer arteries, and greater cardiovascular risk in general population samples.¹²¹³ Researchers investigating these associations in a broader adult population have also confirmed that this biomarker tracks with multiple cardiovascular risk factors.¹⁴

This creates a gap between what observational data suggests (poor K status is linked to worse vascular health) and what supplementation trials have been able to prove (K2 pills do not clearly fix the problem). It may be that vascular calcification takes decades to develop and cannot be meaningfully reversed in a one- or two-year trial. Or it may be that diet-level vitamin K exposure over a lifetime works differently from a supplement bolted onto someone who already has advanced disease. The honest take is that the biology is compelling and the biomarker data lines up, but the intervention trials have not yet delivered the payoff that researchers expected.

MK-7 vs. MK-4 and Why the Form Matters

Vitamin K2 is not a single molecule. It comes in several forms, and the two you will most often see in supplements are MK-4 and MK-7. When researchers compared the two at nutritional-level doses in healthy women, MK-4 was poorly absorbed and did not produce detectable increases in blood levels. MK-7, on the other hand, was well absorbed and significantly raised serum levels.¹⁵ This is why nearly all the cardiovascular trials use MK-7, and why MK-7 dominates the supplement market for heart-health purposes. MK-4 is used at much higher (pharmacological) doses in Japan for bone health, but at the 45-to-180 microgram range most consumers buy, MK-7 is the version your body can actually use.

Vitamin K1, found abundantly in leafy greens, primarily supports blood clotting via the liver, while K2 forms tend to be distributed more widely to tissues outside the liver, including artery walls and bone.¹⁶ This tissue-distribution difference is part of why K2 gets more attention than K1 when the discussion turns to arterial calcification rather than blood clotting.

The Warfarin Question

If you take warfarin (Coumadin), the K2 question gets more complicated. Warfarin works by blocking vitamin K recycling. Any form of vitamin K, whether K1 from spinach or K2 from a supplement, can interfere with warfarin’s anticoagulant effect. A pharmacokinetic analysis of patients undergoing catheter ablation found that vitamin K2 administration at doses above 20 mg caused a measurable decrease in INR, the standard measure of how well warfarin is thinning your blood.¹⁷ Typical K2 supplement doses (90 to 360 micrograms) are far below 20 mg, but even smaller amounts of vitamin K can shift INR when warfarin dosing is tightly calibrated. If you are on warfarin, you should not start or stop a K2 supplement without telling your prescriber.

If you take a direct oral anticoagulant such as apixaban, rivarelbaxaban, or dabigatran instead of warfarin, the concern largely goes away. These drugs work through a different mechanism that does not involve vitamin K at all. A narrative review noted that MK-7 was well tolerated and did not create a hypercoagulable state, and no toxicity has been documented for K1, MK-4, or MK-7 at any dose studied, with no upper tolerance level set by the World Health Organization.²

Special Considerations for Kidney Disease

People with chronic kidney disease deserve a separate mention because they face a particularly cruel combination: they tend to be vitamin K deficient (partly because of dietary restrictions on potassium-rich foods that also happen to be K-rich, and possibly due to impaired vitamin K recycling), and they also develop aggressive vascular calcification that drives hypertension and cardiovascular death.¹⁸¹⁹ You would think K2 supplementation would be a perfect fit here. High-dose MK-7 does reduce levels of the inactive MGP biomarker in kidney patients, confirming that the supplement is getting absorbed and doing what it should at the molecular level. But multiple randomized controlled trials in advanced kidney disease have failed to show that this biochemical improvement translates into better arteries or fewer cardiovascular events.²⁰ The disconnect between what the biomarker shows and what happens clinically is one of the more puzzling gaps in this field.

Safety at Supplement Doses

If your concern is simply whether K2 is safe to take alongside blood pressure medication, the answer for most people is yes. Toxicological testing of synthetic MK-7 found no adverse effects at a single oral dose of 2,000 mg per kilogram of body weight in mice, and no toxicity during 90 days of daily dosing in rats at the highest dose tested.²¹ No cases of toxicity from K1 or any K2 form have been documented in humans, and the European Food Safety Authority has concluded that low-dose menaquinone supplements present no safety concerns.²² K2 does not interact with common classes of blood pressure medications such as ACE inhibitors, ARBs, calcium channel blockers, or diuretics. The only significant drug interaction in routine clinical practice is with warfarin.

Why Some People May Respond and Others Do Not

Genetics appear to play a role in how your body handles vitamin K and therefore how much benefit you might get from supplementation. Researchers studying patients with chronic kidney disease found that specific genetic variants in the VKORC1 gene, which codes for the enzyme that recycles vitamin K, predicted both arterial stiffness and levels of inactive MGP. Patients carrying certain risk variants had stiffer arteries even after adjusting for the usual suspects like age, sex, and blood pressure.²³ This means two people taking the same K2 supplement could have very different outcomes based on how efficiently their bodies recycle and use the vitamin.

Age and menopausal status also seem to influence the response. The strongest positive results in human trials have come from postmenopausal women with already elevated arterial stiffness.⁶ If you are a 35-year-old man with flexible arteries and mild hypertension driven by stress and sodium intake, K2 supplementation is unlikely to move the needle on your blood pressure. If you are a 65-year-old postmenopausal woman whose doctor has mentioned arterial stiffness or calcification, the case for trying K2 is more interesting, though still not definitive.

Animal Research on Salt-Sensitive Hypertension

One intriguing thread comes from animal research rather than human trials. In a study of salt-sensitive hypertension in rats, animals fed a high-salt diet developed elevated blood pressure along with increased expression of proteins in the renin-angiotensin system, the hormonal pathway that regulates blood pressure. When K2 was added to the high-salt diet, blood pressure dropped significantly and expression of those same renin-angiotensin proteins decreased.²⁴ This suggests a possible mechanism beyond calcification, involving direct effects on the hormonal control of blood pressure. But animal findings in blood pressure research have a long history of not translating to humans, so this remains in the category of “interesting lead” rather than actionable evidence.

Food Sources and the Natto Factor

If you prefer getting nutrients from food, the richest dietary source of MK-7 by a wide margin is natto, a fermented soybean dish eaten commonly in parts of Japan. Studies of habitual natto consumers found that people eating three to seven servings per week had meaningfully higher circulating MK-7 levels compared to non-consumers.²⁵ Other fermented foods like certain aged cheeses and sauerkraut contain smaller amounts of various K2 forms. Egg yolks and dark-meat poultry provide modest amounts of MK-4. For most people outside Japan who are not regularly eating natto, supplements are the practical way to get consistent MK-7 intake. A typical cardiovascular-focused dose in clinical trials has been 90 to 360 micrograms of MK-7 per day, with 180 micrograms being the most commonly studied amount.

The bottom line on food versus supplements is that dietary K2 intake in most Western diets is quite low, and achieving trial-level doses through food alone is unrealistic unless you genuinely enjoy natto several times a week. If your goal is specifically to support arterial flexibility, a dedicated MK-7 supplement is more practical than trying to overhaul your diet around K2 content.